low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact venture capital availability and biotech IPO/financing markets, affecting ability to raise capital. Patient enrollment may slow marginally during economic stress but transplant procedures remain medically necessary.

Rising interest rates negatively impact valuation multiples for pre-revenue biotechs as discount rates increase on future cash flows (5-10 years out). Higher rates also reduce risk appetite for speculative growth stocks, compressing biotech sector multiples. Financing costs increase for any debt facilities, though Eledon maintains minimal debt (0.02 D/E ratio). Cash holdings benefit from higher yields on treasury investments.

growth - Attracts speculative biotech investors focused on binary clinical catalysts and potential 5-10x returns on FDA approval. High-risk, high-reward profile appeals to venture capital, biotech-focused hedge funds, and retail momentum traders. Not suitable for value or income investors given negative earnings and no dividend. Recent 37% 3-month rally suggests momentum following positive clinical updates or sector rotation.